7 clinical trials found.
-
A PHASE III DOUBLE-BLINDED MULTICENTER RANDOMIZED STUDY EVALUATING THE EFFICACY AND SAFETY OF NEOADJUVANT TREATMENT WITH ATEZOLIZUMAB OR PLACEBO IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY IN PATIENTS WITH RESECTABLE STAGE II IIIA OR SELECT IIIB NON-SMALL CELL LUNG CANCER
The purpose of this study is to compare the effects, good or bad, of atezolizumab plus chemotherapy (in this study, chemotherapy will be a combination ...
Phase
Interventional
TRIAL ROLE: Principal Investigator
-
A Phase 1 Multiple Dose Study to Evaluate the Safety and Tolerability of XmAb 20717 in Subjects with Selected Advanced Solid Tumors (DUET-2)
The primary purposes of this research study are to determine the safety and tolerability of five dose levels (0.15, 0.3, 1.0, 3.0 and 10.0 milligrams ...
Phase
Interventional
TRIAL ROLE: Principal Investigator
-
A Phase 2 Study of Poziotinib in Patients with Non-Small Cell Lung Cancer (NSCLC) Locally Advanced or Metastatic with EGFR or HER2 Exon 20 Insertion Mutation (ZENITH20)
If you have been diagnosed with Non-Small Cell Lung Cancer that has tested positive for the presence of EGFR or HER2 Exon 20 Insertion (lung ...
Phase
Interventional
TRIAL ROLE: Principal Investigator
-
A Phase II Open-Label Multicenter Single-Arm Study to Investigate the Efficacy and Safety of Atezolizumab as neoadjuvant and adjuvant therapy in Patients with Stage IB II or IIIA resectable and untreated non-small cell lung cancer
The main goal of this phase II study is to evaluate the effectiveness of atezolizumab (a monoclonal antibody against Programmed cell death-ligand (PD-L1)) in ...
Phase
Interventional
TRIAL ROLE: Principal Investigator
-
RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED STUDY OF ERLOTINIB OR PLACEBO IN PATIENTS WITH COMPLETELY RESECTED EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTANT NON-SMALL CELL LUNG CANCER (NSCLC)
The main goal of this phase III clinical trial is to study how well erlotinib (an EGF receptor kinase inhibitor) with adjuvant therapy versus ...
Phase
Interventional
TRIAL ROLE: Principal Investigator
-
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL) A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
This is a randomized phase III study evaluating the benefit of nivolumab (a PD-1 blocking antibody) versus observation for patients with stage IB > ...
Phase
Interventional
TRIAL ROLE: Principal Investigator
-
A Randomized Open-Label Phase 3 Trial of Nivolumab and Ipilimumab versus Platinum-Doublet Chemotherapy in Early Stage NSCLC
The main goal of this study is to assess the potential benefit of nivolumab (a PD-1 receptor blocker antibody) plus ipilimumab (a CTLA4 activator ...
Phase
Interventional
TRIAL ROLE: Principal Investigator
